Hospital del Mar -ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2023

  1. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO

    British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211

2021

  1. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

    Cancer Medicine, Vol. 10, Núm. 4, pp. 1314-1326

2020

  1. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

    Blood, Vol. 135, Núm. 13, pp. 996-1007

  2. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

    Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554

  3. Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era

    European Journal of Haematology, Vol. 104, Núm. 5, pp. 400-408

  4. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

    British Journal of Haematology, Vol. 188, Núm. 6, pp. 888-897

2019

  1. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

  2. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

    Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966

2018

  1. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm

    British Journal of Haematology, Vol. 182, Núm. 4, pp. 534-541

2017

  1. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI

    British Journal of Haematology, Vol. 176, Núm. 6, pp. 918-928